Minodronic acid is used to treat hypercalcemia caused by osteoporosis and malignant tumors. Its inhibitory activity on bone resorption is 2 of disodium incadronate, sodium alendronate and disodium pamidronate. Times, 10 times and 100 times. It has significant benefits in the incidence of spinal fractures and a significant reduction in gastrointestinal side effects. It has now been identified as an effective new anti-osteoporotic drug to prevent fractures. And Ethyl Trans-4-oxo-2-butenoate CAS 2960-66-9 is an important intermediate of Minodronic Acid.
Osteoporosis is a systemic system in which bone microstructure is damaged, bone mineral components and bone matrix are constantly reduced, bone is thinner, bone trabeculae are reduced, bone fragility is increased, and the risk of fracture is increased Disorders of bone metabolism. Generally divided into two categories, namely primary osteoporosis and secondary osteoporosis.